Slingshot members are tracking this event:

Novartis' (NVS) Dual Combination Bronchodilator Inhalation Powder for Treatment of Airflow Obstruction in Patients with Chronic Pulmonary Disease Approved by FDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 29, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Utibron Neohaler, Chronic Bronchitis, Emphysema, Chronic Obstructive Pulmonary Disease, Cop